# Lisata Therapeutics, Inc. (LSTA) · Edgar & Edgarette company card

> Lisata Therapeutics (LSTA) saw revenue fall 83.0% in FY2025 to $0 million, operating margin -10711% against a -3.8% median for pharmaceutical preparations, equity 83.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 320017 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/LSTA) · [JSON](https://www.pops4.com/boards/company/LSTA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $170,000 |
| Revenue growth, 1 year | -83.0% |
| Revenue growth per year | -44.7% |
| Operating margin | -10711.2% (prior year -2240.9%) |
| Net margin | -9756.5% |
| Operating cash flow | −$16M |
| Capital spending | $28,000 |
| Free cash flow | −$16M |
| Cash | $16M |
| Long-term debt | — |
| Total assets | $18M |
| Total equity | $15M |
| Equity ÷ assets | 83.7% |
| Return on equity | -111.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -100.26 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative (-$15.9M in FY2025); operating loss: a margin of -10711.2% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $170K (FY2025). Experience: revenue down 83.0% on the year, down 44.7% a year over 9 years; operating margin -10711.2%, down from -2240.9%. Soundness: equity 83.7% of assets, return on equity -111.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $45K and $81K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -10711.2% against a -3.8% median; growth -83.0% against 13.7%.

Range logged 2026-09-20, receipt 28cfba6d9b62bd97, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-08-04 ([filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/0001140361-26-031028-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-10-14 ([filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126039602/0001140361-26-039602-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-19 · [filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126039986/0001140361-26-039986-index.htm)
- 8-K · filed 2026-10-14 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126039602/0001140361-26-039602-index.htm)
- 8-K · filed 2026-09-17 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/320017/000032001726000038/0000320017-26-000038-index.htm)
- 8-K · filed 2026-08-04 · 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/0001140361-26-031028-index.htm)
- 8-K · filed 2026-07-24 · 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/0001140361-26-029541-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000320017.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=320017

## Cite

POPS4, Edgar & Edgarette: Lisata Therapeutics, Inc. (LSTA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/LSTA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.